you, Doug. Thank
last mentioned, Doug from our million, a increase year. XX% XXX second As quarter were revenues
We are execution. pleased very our team's with
increased increased XX% year-over-year to $XX while acquisition driven Services Genoptix million gains. XX% revenue XX%, test by Clinical market to share increased Clinical continued and revenue the volume per $XXX.
Revenue X%, per test $XX, decreased or sequentially. about
did mix, we include a quarter, greater anticipated which managed will vary volatility quarter in While contract portion to to test good finalization contracts. from our necessary revenue from to negotiations the is Genoptix decline this than incur of of attributable care
and feel test be per we third to these to expect that negotiations Importantly, flat confident up the slightly quarter. we are behind us in revenue
high water increased to the internal our and of for which was projections. revenue Services a almost Pharma mark $XX XX% ahead is million, division new
compared of with over XX% half year. Services Pharma XXXX, the is For up first last revenue
million the We chunk performance $XXX significant new revenue. revenue to booked converted that QX quarter in to second quarter-over-quarter and increased our reporting backlog of despite a business of strong $XX million, backlog
modality. cancellations an Importantly, unusually every and level in from we growth broad-based high normalized saw test nearly QX, across
basis up million to increase $XX million Combined a margin the per prior test, growth, average This gains, on XXX gross contribution revenue to XX%, year-over-year Gross of and cost annual was impact efficiencies. from revenue improved productivity of higher just points growth. profit This the over $XX $XX driven XX% represents the year. volume by million, XX.X%. increased by improvement
outstanding, the Pharma first company growth accommodate Division. expected our reaching in add our at scale gross to to As The be as more we Pharma Clinical was expected, for margin are ever. beginning to is in employees Notably, modestly sequentially XX% gross with margin which time the services they margins. line gross business declined to reach continued Services
clinical average and per a on known of impact X% growth. employees during per as reflecting scale increased also $XXX to Test” hired Our quarter our decreased our our increasing reflecting basis on Cost support per pro-forma year-over-year the cost-of-goods-sold efficiency. test focus sequentially, “Cost rapid to X% Test additional the
decreased Administrative to & General synergies. G&A addition sequentially expense year-over-year by of to to expenses, increased fees due and due $X $XX XX% million acquisition related decreased the lower professional transaction Genoptix. million expenses
new acquisition million, size of year-over-year, expanded costs costs sales and the more development, our driven and continued the investments XXX% initiatives. than increased team. Sales of Marketing Genoptix to XX% by year-over-year FDA & including our Development Research $XX by test in driven by increased
GAAP quarter income quarter $X in second Second million the of $XXX,XXX of was compared XXXX. net a to net loss
related its and, adjusted with income order earnings and the per net our income appropriate and a in net of shareholders non-cash We the GAAP have company items to share, income across to to earnings in adjust more that operations believe or how refer this certain to basis, compare table diluted adjusted measure as, to loss included we one-time the per available release. share on net are We a a common to costs. these on if calculated applicable, basis true periods, consistent exclude
a net quarter. of to was Adjusted compared $XX was the XX% the in $X.X income $X.XX record million Adjusted to increased year-over-year million Adjusted the prior diluted EBITDA versus XXXX. $X.XX quarter for year. in million EPS $X.X second
in $XXX with DSO We million in debt. million $XXX and at healthy exited cash QX XX days. remained
and related While up is inflows saw three days cash DSO first was few this days timing the July. we increase in of substantial sequentially,
address cash I flow. guidance, Before discuss want to our operating QX I XXXX some time updated take to
of $X $X HDC, attributed many we million their no DSO capital. we the of to a increase timing-related saw remainder that in cash, but any big know million the During accounts is normal receivable discussed you of with unusual led fluctuations a in as This million uptick just use due for another cash the I working payment to to in to longer partially $X sequential piece our use as quarter, is is technology, business. which final the
adjusted business quarters. profitability flow our underlying future believe EBITDA as serves the good our in for to expect improve to cash proxy continue operating of and We a
of We to $XXX million updating now million million. XXXX $XX We million of and consolidated are second full-year million than expect our million. quarter guidance $XXX The $XX range the reflects guidance Adjusted $XXX $XXX to versus previous revenue guidance. expect of revenue the in our now our to better earnings EBITDA We to increase million guidance of versus previous be in range to to expected million results. in $XX be $XX
Fee comment on briefly Finally, released I’d the like last Schedule Physician night. proposed to
Schedule. XX% than of the less a Medicare we billed Fee revenue As under Physician payments generate reminder, our from
that in IHC neutral Based will increases the reductions net on to and offset by in believe our modest FISH. preliminary Flow NeoGenomics impact analysis, modest XXXX, in we with be
I commentary back turn to Doug XXXX to our provide the additional will on some over and now initiatives call opportunities. key
